Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 43, Issue 3, Pages 188-205Publisher
CELL PRESS
DOI: 10.1016/j.tips.2021.12.001
Keywords
-
Categories
Funding
- Deutscher Akademischer Austauschdienst (DAAD)
- German Research Foundation [WE2554/13-1, WE2554/15-1]
- University of Twente
Ask authors/readers for more resources
This review discusses the role of lipoxygenases (LOXs) and their signaling pathways in chronic liver diseases (CLDs), as well as their potential as diagnostic biomarkers and therapeutic targets for CLDs.
Chronic liver diseases (CLDs) caused by viral infections, alcohol/drug abuse, or metabolic disorders affect millions of people globally and have increased mortality owing to the lack of approved therapies. Lipoxygenases (LOXs) are a family of multifaceted enzymes that are responsible for the oxidation of polyunsaturated fatty acids (PUFAs) and are implicated in the pathogenesis of multiple disorders including liver diseases. This review describes the three main LOX signaling pathways - 5-, 12-, and 15-LOX - and their involvement in CLDs. We also provide recent insights and future perspectives on LOX-related hepatic pathophysiology, and discuss the potential of LOXs and LOX-derived metabolites as diagnostic biomarkers and therapeutic targets in CLDs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
